By Reuters Staff
FRANKFURT (Reuters) – Pfizer Inc and BioNTech SE have asked the U.S. health regulator to relax requirements for their COVID-19 vaccine to be stored at ultra-low temperatures, potentially allowing for it to be kept in pharmacy freezers, they said on Friday.
An approval by the Food and Drug Administration (FDA) could send a strong signal to other regulators around the world that may potentially ease distribution of the shot in lower-income countries.
The companies have submitted new temperature data to the U.S. Food and Drug Administration to support an update to the current label that would allow vaccine vials to be stored at -25 to -15 degrees Celsius (-13°F to 5°F) for a total of two weeks.
The current label requires the vaccine to be stored in an ultra-cold freezer at temperatures between -80ºC and -60ºC (-112ºF to -76ºF), meaning it has to be shipped in specially designed containers.
The shot’s cold-storage requirements set off a scramble among U.S. states at the beginning of the rollout for dry ice, in which it can be stored temporarily when there are no specialized freezers available, for instance in rural areas.
Pfizer/BioNTech’s vaccine, along with Moderna Inc’s two-dose shot, has already won U.S. emergency-use authorization and is being widely distributed as part of the country’s mass vaccination efforts.
The update from the drugmakers comes as two studies from Israel found that the vaccine greatly reduced virus transmission, and the shot was backed by one of South African government’s top advisers.
The new data also will be submitted to global regulatory agencies within the next few weeks, the two companies said.
A BioNTech spokeswoman declined to provide more details on the timing and which agencies would be contacted.
“The data submitted may facilitate the handling of our vaccine in pharmacies and provide vaccination centers an even greater flexibility,” BioNTech Chief Executive Ugur Sahin said.
BioNTech has said it imposed long-term storage and transportation requirements of minus 70 degrees out of caution because it had started stability and durability tests on its vaccine relatively late.
Even though it launched its COVID-19 vaccine development programme as early as January 2020, working on four compounds in parallel, it did not decide until July which of the four to proceed with, and only then started stability tests.
If approved, the less onerous storage requirements would provide significant logistical relief for the roll-out of the vaccine worldwide, particularly in lower-income countries that do not have the necessary infrastructure to maintain ultra-cold conditions.
The World Health Organization’s COVAX global vaccine-sharing program has so far limited distribution of Pfizer-BioNTech vaccines to just a few countries, partly out of concern over a lack of infrastructure in developing nations.
The WHO said it was hopeful that eased requirements could broaden its reach.
“We are aware of reports of this and look forward to seeing the data. If proven correct, this could make roll-out of the vaccine easier in all countries, and particularly in low-income ones,” it said.
Moderna’s product, which like Pfizer’s is based on so-called messenger RNA molecules, is already cleared here for storage at -25 to -15 degrees Celsius.
Reporting by Manojna Maddipatla and Ankur Banerjee in Bengaluru, Ludwig Burger in Frankfurt, John Miller in Zurich; Editing by Shounak Dasgupta, Anil D’Silva and Jan Harvey
FILE PHOTO: A medical worker fills a syringe with a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine as Japan launches its inoculation campaign, at Tokyo Medical Center in Tokyo, Japan February 17, 2021. Behrouz Mehri/Pool via REUTERS/File Photo